Testicular diffuse large B-cell lymphoma. Clinical lecture and case report
https://doi.org/10.29413/ABS.2023-8.5.8
Abstract
Lymphoma is a heterogeneous group of lymphocyte malignancies that may involve lymphatic tissue, bone marrow, or extranodal sites. The lecture provides a brief overview of the current state of the problem of diagnosis and treatment of primary testicular lymphoma. Primary testicular lymphoma (PTL) is a rare lymphoid malignancy. Though it is rare, PTL is the most common type of testicular tumor in men over 60 years of age. The most common histological type is diffuse large B-cell lymphoma. To date, there are no well-documented etiological or risk factors for PTL. In contrast to other common testicular neoplasms, there was no statistically significant association of PTL with cryptorchidism, trauma, chronic orchitis, or infertility. Ultrasound is generally the first-line imaging method used to characterize testicular lesions. PTL manifests itself in the form of a hypoechoic formation, which can take the form of either a single large formation or multiple small formations that occupy most of the testicular parenchyma or completely replace it. Systemic treatment, including orchiectomy, chemotherapy, radiation therapy, and intrathecal prophylaxis, is necessary for all patients with PTL. In addition to achieving complete remission, the goal of PTL treatment is to prevent recurrences in the contralateral testis and central nervous system. The presented information is supplemented by our own observation and images. Personal medical data is published with the written consent of the patient. In our case, the patient’s age was 38 years, which does not fall into the specified age group for primary testicular lymphoma. In our opinion, the publication of this clinical case and analysis of scientific literature on this topic are relevant.
About the Authors
K. B. Lelyavin
Irkutsk State Medical Academy of Postgraduate Education – Branch Campus of the Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Kirill B. Lelyavin – Dr. Sc. (Med.), Associate Professor at the Department of Emergency Medical Services and Disaster Medicine
Yubileyniy 100, Irkutsk 664049
A. V. Taranenko
Irkutsk State Medical Academy of Postgraduate Education – Branch Campus of the Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Andrey V. Taranenko – Cand. Sc. (Med.), Teaching Assistant at the Department of Oncology
Yubileyniy 100, Irkutsk 664049
V. G. Bryukhanov
Center for Magnetic Resonance Imaging “MRT-Lider”
Russian Federation
Russian Federation
Vladimir G. Bryukhanov– Radiologist
Karla Liebknekhta str. 9, Irkutsk 664007
References
1. Menter T, Ernst M, Drachneris J, Dirnhofer S, Barghorn A, Went P, et al. Phenotype profiling of primary testicular diffuse large B-cell lymphomas. Hematol Oncol. 2014; 32: 72-81. doi: 10.1002/hon.2090
2. Kazakevich VI, Mitina LA, Skreptsova NS, Vostrov AN, Mayorova MV, Prozorova EV, et al. Ultrasound examination in lymphoma with pelvic involvement. Ultrasound and Functional Diagnostics. 2015; 4S: 75-76. (In Russ.).
3. Curling TB. A practical treatise on the diseases of testis and of the spermatic cord and scrotum. Philadelphia; 1856.
4. Malassez M. Lymphadenome du testicule, rapport sur la candidature de M. Letulle, interne des hospitaux au titre de member adjoint. Bull Soc Anta (Paris). 1877; 52: 176-178.
5. Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin’s lymphoma. Med Sci (Basel). 2021; 9(1): 5. doi: 10.3390/medsci9010005
6. Lewis WD, Lilly S, Jones KL. Lymphoma: Diagnosis and treatment. Am Fam Physician. 2020; 101(1): 34-41.
7. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375-2390. doi: 10.1182/blood-2016-01-643569
8. Palumbo C, Mazzone E, Mistretta FA, Knipper S, Tian Z, Perrotte P, et al. Primary lymphomas of the genitourinary tract: A population-based study. Asian J Urol. 2020; 7(4): 332-339. doi: 10.1016/j.ajur.2019.11.002
9. Ma RZ, Tian L, Tao LY, He HY, Li M, Lu M, et al. The survival and prognostic factors of primary testicular lymphoma: Two-decade single-center experience. Asian J Androl. 2018; 20(6): 615-620. doi: 10.4103/aja.aja_73_18
10. Shahab N, Doll DC. Testicular lymphoma. Semin Oncol. 1999; 26: 259-269.
11. Tumyan GS, Kovrigina AM, Timofeeva OL, Probatova NA, Sholokhova EN, Tupitsyn NN, et al. Features of the clinical course and prognosis of patients with non-Hodgkin lymphoma with primary localization in the testicle. Journal of Modern Oncology. 2006; 8(4): 22-26. (In Russ.).
12. Ahmad SS, Idris SF, Follows GA, Williams MV. Primary testicular lymphoma. Clin Oncol (R Coll Radiol). 2012; 24(5): 358-365. doi: 10.1016/j.clon.2012.02.005
13. Chen B, Cao DH, Lai L, Guo JB, Chen ZY, Huang Y, et al. Adult primary testicular lymphoma: clinical features and survival in a series of patients treated at a high-volume institution in China. BMC Cancer. 2020; 20(1): 220. doi: 10.1186/s12885-020-6711-0
14. Lemma SA, Kuusisto M, Haapasaari KM, Sormunen R, Lehtinen T, Klaavuniemi T, et al. Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma. Carcinogenesis. 2017; 38(8): 812-820. doi: 10.1093/carcin/bgx061
15. Roberts WC, Glancy DL, Devita VT. Heart in malignant lymphoma (Hodgkin’s disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides): A study of 196 autopsy cases. Am J Cardiol. 1968; 22: 85-107. doi: 10.1016/0002-9149(68)90250-6
16. Yasen Z, Kazzazi F, Ioannides K, Velmurugan S, Zegocki K, Li C. A case at crossroads-urological presentation, cardiac complication and haematological diagnosis: Should imaging be pursued prior to orchidectomy at all costs? J Surg Case Rep. 2021; 2021(5): rjab177. doi: 10.1093/jscr/rjab177
17. Horne MJ, Adeniran AJ. Primary diffuse large B-cell lymphoma of the testis. Arch Pathol Lab Med. 2011; 135(10): 1363-1367. doi: 10.5858/arpa.2010-0158-RS
18. Scott DW, Gascoyne RD. The tumor microenvironment in B cell lymphomas. Nat Rev Cancer. 2014; 14(8): 517-534. doi: 10.1038/nrc3774
19. Moses K, Brandau S. Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells. Semin Immunol. 2016; 28: 187-196. doi: 10.1016/j.smim.2016.03.018
20. Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev. 2007; 18: 171-182. doi: 10.1016/j.cytogfr.2007.01.015
21. Brandau S, Dumitru CA, Lang S. Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol. 2013; 35: 163-176. doi: 10.1007/s00281-012-0344-6
22. Leivonen SK, Pollari M, Brück O, Pellinen T, Autio M, Karjalainen-Lindsberg ML, et al. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica. 2019; 104(2): 338-346. doi: 10.3324/haematol.2018.200105
23. Oishi N, Kondo T, Nakazawa T, Mochizuki K, Tanioka F, Oyama T, et al. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses. Pathol Int. 2015; 65(10): 528-535. doi: 10.1111/pin.12336
24. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell ymphoma. N Engl J Med. 2018; 378(15): 1396-1407. doi: 10.1056/NEJMoa1801445
25. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019; 94(5): 604-616. doi: 10.1002/ajh.25460
26. Mazzu D, Jeffrey RB Jr, Ralls PW. Lymphoma and leukemia involving the testicles: Findings on gray-scale and color Doppler sonography. AJR Am J Roentgenol. 1995; 164: 645-647. doi: 10.2214/ajr.164.3.7863887
27. Benevolo G, Stacchini A, Spina M, Ferreri AJ, Arras M, et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood. 2012; 120: 3222-3228. doi: 10.1182/blood-2012-04-423095
28. Pollari M, Leivonen SK, Leppä S. Testicular diffuse large B-cell lymphoma-clinical, molecular, and immunological features. Cancers (Basel). 2021; 13(16): 4049. doi: 10.3390/cancers13164049
29. Ballen KK, Hasserjian RP. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-2004. A 31-year-old man with bilateral testicular enlargement. N Engl J Med. 2004; 350(20): 2081-2087. doi: 10.1056/NEJMcpc049003
30. Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: Final results of an international phase II trial. J Clin Oncol. 2011; 29(20): 2766-2772. doi: 10.1200/JCO.2010.31.4187
31. Gundrum JD, Mathiason MA, Moore DB, Go RS. Primary testicular diffuse large B-cell lymphoma: A population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009; 27(31): 5227-5232. doi: 10.1200/JCO.2009.22.5896
32. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German high-grade non-Hodgkin’s lymphoma study group (DSHNHL). Ann Oncol. 2007; 18(1): 149-157. doi: 10.1093/annonc/mdl327
33. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010; 21(5): 1046-1052. doi: 10.1093/annonc/mdp432
34. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003; 21(1): 20-27. doi: 10.1200/JCO.2003.11.141
35. Gundrum JD, Mathiason MA, Moore DB, Ronald SG. Primary testicular diffuse large B-cell lymphoma: A population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009; 27: 5227-5232. doi: 10.1200/JCO.2009.22.5896
36. Mazloom A, Fowler N, Medeiros LJ, Iyengoar P, Horace P, et al. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: The M.D. Anderson Cancer Center experience. Leuk Lymphoma. 2010; 51: 1217-1224. doi: 10.3109/10428191003793358
37. Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: Results of a phase II Nordic Lymphoma Group study. Ann. Oncol. 2013; 24: 1385-1392. doi: 10.1093/annonc/mds621
38. Agha RA, Franchi T, Sohrabi C, Mathew G, Kerwan A. The SCARE 2020 guideline: Updating consensus Surgical CAse REport (SCARE) guidelines. Int J Surg. 2020; 84: 226-230. doi: 10.1016/j.ijsu.2020.10.034
Review
For citations:
Lelyavin K.B., Taranenko A.V., Bryukhanov V.G. Testicular diffuse large B-cell lymphoma. Clinical lecture and case report. Acta Biomedica Scientifica. 2023;8(5):81-91. https://doi.org/10.29413/ABS.2023-8.5.8
Views:
744
.png)
Email this article 
